Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?

Area of Science:

• Hematology
• Genetic Medicine
• Transplantation Immunology

Background:

• Sickle cell disease (SCD) is a prevalent inherited blood disorder.
• While treatments have improved pediatric survival, adults with SCD face significant morbidity and mortality.
• Existing therapies offer symptomatic relief but not a cure for most patients.

Purpose of the Study:

• To review current curative therapies for sickle cell disease.
• To compare the potential benefits and drawbacks of genetic therapies and allogeneic hematopoietic cell transplantation (allo-HCT).
• To assess the long-term implications and accessibility of these advanced treatments.

Main Methods:

• Review of recent advancements in genetic therapies for SCD.
• Analysis of outcomes and challenges associated with allogeneic hematopoietic cell transplantation (allo-HCT).
• Comparative assessment of efficacy, safety, cost, and late health effects of genetic therapies versus allo-HCT.

Main Results:

• Two FDA-approved genetic therapies can reduce acute pain events but may not offer a definitive cure.
• Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative option, with recent advances mitigating previous donor limitations and risks.
• Genetic therapies are approximately five times more expensive than allo-HCT and may involve myeloablation with associated late health effects.

Conclusions:

• Both genetic therapy and allo-HCT present potential cures for the majority of individuals with SCD.
• Allo-HCT may be a more favorable curative option than genetic therapies due to its lower cost, reduced need for myeloablation, and fewer associated late-health effects.